Sitemap

NKM in Brief

Ningbo Krka Menovo (NKM) pharmaceutical Co., Ltd was established in December 2017 as a joint venture of Krka, d. d., Novo mesto (Krka) and Ningbo Menovo Pharmaceutical Co.,Ltd. (Menovo). NKM represents an important part of Krka’s business development strategy in China.

NKM focuses on the development, production, registration and sales of finished pharmaceutical products in China. It will focus also on production of pharmaceuticals for Krka’s other markets, especially European.

So far, NKM has already completed several technology transfer projects and started production and sales of finished pharmaceutical products for the EU markets. The company has reached several milestones in the product development for the Chinese market, of which bioequivalence studies and product registration procedures are most notable.